Search clinical trials for: Controlled-Release Oxycodone Hydrochloride 40 mg tablet

Total 562 results

Mallinckrodt

Completed

Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

Healthy

United States
Ensysce Biosciences
Dr. Vince Clinical Research

Completed

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users

Recreational Drug Use

United States
Mallinckrodt

Completed

Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

Healthy

United States
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Mallinckrodt

Completed

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets

Healthy

United States
Mallinckrodt

Completed

Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

Healthy

United States
Mallinckrodt

Completed

Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

Healthy

United States
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OTR Tablet 40 mg Fasted-state Bioequivalence Study

Chronic Pain

China
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
Purdue Pharma LP

Completed

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

Opioid Analgesia

United States, Australia, Finland, New Zealand
Purdue Pharma LP

Completed

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Pain

United States, Israel
Mundipharma Research GmbH & Co KG

Completed

OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

Chronic Osteoarthritis

Spain, Belgium, Finland, Czechia, Germany, Hungary
Teva Pharmaceuticals USA

Completed

Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions

Healthy

United States
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
Luye Pharma Group Ltd.

Recruiting

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Generalized Anxiety Disorder

China
Cingulate Therapeutics

Completed

CTx-1301 Comparative Bioavailability Study

ADHD

United States
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OTR Tablet 40 mg Fed-state Bioequivalence Study

Chronic Pain

China
Teva Pharmaceuticals USA

Completed

Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions

Healthy

United States
Ensysce Biosciences
PRA Health Sciences

Completed

Evaluation of Oral PF614 Relative to OxyContin

Healthy Volunteers

United States
Istituto Oncologico Veneto IRCCS

Completed

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Glioblastoma Multiforme

Italy
Pfizer

Completed

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

Healthy

United States
Purdue Pharma LP

Completed

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Low Back Pain

United States, Poland, Czech Republic, Italy
Overseas Pharmaceuticals, Ltd.
Virginia Contract Research Organization Co., Ltd.

Terminated

To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets in Normal Healthy Volunteers

Pain Control

Taiwan
Purdue Pharma LP

Completed

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Pain

United States, Israel, Spain, United Kingdom, Greece, Hungary, New Zealand, Romania
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Pfizer

Withdrawn

A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation

Smoking Cessation
Ensysce Biosciences

Completed

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users

Recreational Drug Use

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg

Healthy

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Prescription Opioid Effects in Abusers Versus Non-Abusers

Substance-Related Disorders | Opioid-Related Disorders

United States
Shanghai Mental Health Center

Not yet recruiting

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

Somatic Symptom

China
Kremers Urban Development Company

Completed

Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets

Healthy

United States
Istituto Oncologico Veneto IRCCS
Bayer

Not yet recruiting

Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial) (MIRAGE)

Meningioma, Malignant

Italy
Mundipharma Research GmbH & Co KG

Completed

A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy

Pain | Constipation

United Kingdom
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Alfredo Berruti

Recruiting

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib (MERIDIAN)

Carcinoma Prostate

Italy
Luye Pharma Group Ltd.

Not yet recruiting

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

Major Depressive Disorder
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition

Fasting

India
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet

Metformin XR BE Study in Healthy Volunteers With Single and Multiple Dose

Indonesia
Max Zeller Soehne AG

Completed

Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117

Healthy

Germany
University of Florida

Recruiting

The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults

Pain

United States
Pfizer
Syneos Health

Completed

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers

Healthy

Canada
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OTR Tablet 10 mg Fasted-state Bioequivalence Study

Chronic Pain

China
Valenta Pharm JSC

Completed

Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
University of Florida
National Institute on Drug Abuse (NIDA)

Recruiting

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

Pain

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Healthy

3

Subscribe